Most Popular

1
Blinken calls on China to press N. Korea to end its 'dangerous' behavior
2
S. Korea, Japan could consider simplified entry agreement: Seoul official
3
New celebrity-endorsed therapy for face contouring requires only a pair of rubber bands
4
[Weekender] How DDP emerged as an icon of Seoul
5
Doctor group's incoming head renews call for govt. to scrap medical school quota hike for dialogue

6
Tensions heighten ahead of first president-opposition chief meeting
7
'The Roundup: Punishment' becomes fastest 2024 film to top 2 mln admissions
8
[Music in drama] An ode to childhood trauma
9
New head of doctors' association vows war in case of disadvantage to medical professors
10
Seoul to provide housing subsidy to married couples with newborns

NewsletterSubscribe

Start your day with a roundup of key stories from The Korea Herald with news and comment on all that’s happening in Korea.

Celltrion’s biosimilar prescribed over 100,000 times in Europe

By 황유미

Published : Aug. 30, 2016 - 17:31

- Link copied

[THE INVESTOR] Biopharmaceutical company Celltrion announced on Aug. 30 that its biosimilar Remsima has been prescribed for more than 105,000 patients in Europe by end-June since its launch in August 2013.

As the number of European patients who were prescribed Janssen’s Remicade (infliximab), the original drug to treat rheumatoid arthritis and autoimmune diseases, is estimated to be about 260,000, the biosimilar version is taking up about 40 percent of its market share, according to the company.

By Hwang You-mee (glamazon@heraldcorp.com)

Celltrion’s biosimilar prescribed over 100,000 times in Europe

More from Headlines